Agalimmune
Agalimmune were a small biotech company at an early stage of development of a rabbit poly-clonal antibody-based therapy. They approached Oxford cancer researchers who advised on the development of a synthetic mimic and then developed a trial protocol as an investigator led study. We were in the process of applying for grant funding to launch the study locally when they were bought out for $12M by BioLineRx who sponsored the study and subsequent clinical development.